Your browser doesn't support javascript.
loading
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
Vormoor, B; Veal, G J; Griffin, M J; Boddy, A V; Irving, J; Minto, L; Case, M; Banerji, U; Swales, K E; Tall, J R; Moore, A S; Toguchi, M; Acton, G; Dyer, K; Schwab, C; Harrison, C J; Grainger, J D; Lancaster, D; Kearns, P; Hargrave, D; Vormoor, J.
Afiliação
  • Vormoor B; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Veal GJ; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Griffin MJ; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Boddy AV; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Irving J; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Minto L; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Case M; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Banerji U; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Swales KE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K.
  • Tall JR; The Royal Marsden Hospital, Sutton, UK.
  • Moore AS; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K.
  • Toguchi M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K.
  • Acton G; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K.
  • Dyer K; The Royal Marsden Hospital, Sutton, UK.
  • Schwab C; Astex Pharmaceuticals, Cambridge Science Park, Cambridge, UK.
  • Harrison CJ; Cancer Research UK Centre for Drug Development, London, UK.
  • Grainger JD; Cancer Research UK Centre for Drug Development, London, UK.
  • Lancaster D; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Kearns P; Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Hargrave D; Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Vormoor J; Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK.
Pediatr Blood Cancer ; 64(6)2017 06.
Article em En | MEDLINE | ID: mdl-27905678
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ureia / Benzimidazóis / Leucemia / Inibidores de Proteínas Quinases / Aurora Quinases / Proteínas de Neoplasias Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ureia / Benzimidazóis / Leucemia / Inibidores de Proteínas Quinases / Aurora Quinases / Proteínas de Neoplasias Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article